Cases & Deals

  • Home
  • Practices
  • Xencor develops patent portfolios for various XmAb® cytokine and bispecific antibodies and uses thereof

Share

Xencor develops patent portfolios for various XmAb® cytokine and bispecific antibodies and uses thereof

October 2021

Client(s) Xencor, Inc.

Jones Day represents Xencor, Inc. in developing global patent portfolios related to various XmAb® cytokine and bispecific antibody clinical candidates and uses thereof for the treatment of cancer and other disorders.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.